.

.
marylin monroe
Showing posts with label side effects. Show all posts
Showing posts with label side effects. Show all posts

Sucralose, Carcinogen or Sweet Relief? Part III: DNA Breaks + Drug & Hormone Interactions | Sucralose, White Death?

Fearmongering fake, or true biohazard. This is the life-or-death- question this last installment of the sucralose trilogy will have to answer.
It's time for the third and last installment of the SuppVersity sucralose review trilogy. Looking back at the list of issues in the first installment of this series, it appears as if the one thing that was still left to discuss are the mutagenic, pro-carcinogenic and tissue damaging effects of sucralose and its potentially endocrine disrupting metabolic / thermic byproducts. It goes without saying that the previously discussed and largely rebutted effects on blood glucose management, body weight gain and even the balance of your gut microbiome would be hardly significant, if today's analysis confirms that the use of Splenda© & Co was linked to direct mutagenic, carcinogenic or general toxic effects.

Put your hazard suits on, folks!

It's obvious that I got carried away by my imagination, when I wrote this subheading, but if the same wasn't true for the author of the repeatedly cited press release, many of us are about to suffer the consequences of the potential unsafety of the hitherto unknown sucralose metabolites in our guts, pretty soon.
This is part III of a multi-part series:

Sucralose, insulin, glucose, GLP-1

Appetite, Obesity & Gut Health

Cancer, Drug & Hormone Interact.
I know that Mark Sisson likes to says this, but this website is not written by a machine, but by a man who has the same "short" 24h days you have... basically, what I am trying to say is that I had to split this review of the review into a "trilogy" - and be honest, you wouldn't want an article thrice as long as this one, would you?
In fact, you don't even have to go searching the databases for hours to find evidence that would support the claim that some of these metabolits that supposedly arise, while sucralose passes through our digestive tract (hitherto we have only highly debated evidence from rodent studies that there are any metabolits at all, by the way) could be pretty nasty bastards. In their 2008 paper, Abou-Donia et al. (2008), whose rodent study is still the only one to support the claim that the consumption of sucralose (HED 42mg/day or more over 3 months) will lead to a "reduction in the number and balance of beneficial bacteria in the gastrointestinal tract" (quote from press release; learn more), cite a study, for example, in which Sasaki et al. (2002) confirmed that sucralose exerts genotoxic effects. This does not mean that the DNA breaks / changes the researchers observed lead to the development of cancer, but the in vivo comet essay the researchers used, is generally considered a very reliable indicator of the genotoxicity of the tested compound in a particular body part (Brendler-Schwaab. 2005).
Believe it or not, but aspartame is one out of three sweeteners Sasaki et al. tested that are not genotoxic | more about aspartame
It's not just sucralose: I guess it's only fair, if I point out that Sasaki's study showed that sodium cyclamate, saccharin, sodium saccharin, likewise artificial sweeteners, caused DNA damage to various organs, as well. The dosage that was necessary to trigger these effects was yet unrealistically high: 2000mg/kg for sucralose and sodium cyclamate, 1000mg/kg for saccharin and sodium saccharin - for humans that would be 26g and 13g of pure sweetener every day! Ah, before I forget to mention that: Acesulfame-K, aspartame and stevia were also tested and found to be benign.
The absence of direct evidence of real-world negative effects, the insignificance of the long-demonstrated weak muatgenicity in the mouse lymphoma mutation assay, both, the WHO and the FDA have confirm ed in independent reports (WHO, 1989; U.S. FDA, 1998), is thus probably the reason the compound has still been approved as a food additive in 1991 - initially in Canada and Australia, then in the rest of the federally regulated world (Canada & Australia, 1993; New Zealand, 1996; US, 1998; EU, 2004). Today, the sales in sucralose alone account for 27.9% of the $1.146 billion global highpotency sweetener market (Leatherhead Food Research, 2011). No wonder, after all, sucralose is utilized in thousands of food, beverage, and pharmaceutical products in North America, Latin America, Europe, the Middle East, and the Asia-Pacific region (Schiffman. 2013).

So what does the (almost) "real-world" evidence say?

It's unquestionably debatable whether this was a good idea or a tragic mistake, but without corresponding "real-world" assays from longer-term rodent studies, the damage that occurs in response to the DNA breaks that have been observed in in-vitro studies may well be so small that the DNA repair machinery that operates in our bodies 24/7 can fix it easily. In this case, our coroners would probably find a similar increase in non-neoplastic findings (=non-cancerous, often minimal tissue growth, where it does not belong), as they were reported by Mann et al. (see list below the red box) in a combined chronic toxicity/carcinogenicity study of sucralose in Sprague–Dawley rats and a carcinogenicity study of sucralose in mice (Mann. 2000a, 2000b). Direct evidence for the development of cancer and/or the potential epigenetic changes is yet, as Schiffman & Rother have to concede, simply not available.
Don't bake your arginine-containing anti-diabetes cookies with sucralose
Sucralose + heat - a potentially hazardous combination: Contrary to often cited claims by Barnd & Jackson (1990) or Miller, et al. (1999), there is more recent evidence that suggest sucralose is not heat stable (Jahn & Yaylayan. 2010; Schiffman. 2012; Schiffman and Abou-Donia. 2012). According to these more recent papers ther are a whole host of thermal degradation products in cookies. Whether these byproducts pose a health risk is however not know for most of them. Only the chloropropanols that form when the reaction occurs in the presence of gylcerol (Rahn. 2010), are well-known genotoxic, carcinogenic, and tumorigenic compounds (Biles. 1983; Cho. 2008; Tritscher. 2004; SCF. 2001; WHO, 2002).
Quite the contrary, if you look at the literature as a whole, there is plenty of data that would support the decision of the Australian, US and EU to approve sucralose as a food additive, e.g.:
  • No toxic effects even with 3% of total dietary intake in Sprague–Dawley rats; all non-neoplastic findings that occurred were of no toxicological significance and are part of the regular aging process of this strain of rats (Mann. 2000a)
  • No positive results in in vivo chromosome aberration test in rats and two separate micronucleus tests in mice with doses of up to 2,000mg/kg for 5 days (Brusick. 2010)
  • No effect on organ and general development, when fed to pregnant rats and rabbits in HEDs of up to 26g (rats) and 9g, respectively (Kille. 2000)
I don't want to discard the existing evidence Schiffman et al. cite in favor of their "sucralose is the devil" hypothesis, but results of the vast majority of these studies can hardly be considered relevant with respect to the question whether the comparatively small amount of sucralose that may be present in your foods, supplements or whatever you may be sweetening with sucralose is going to harm you or your DNA:
  • The death of one out of 10 mice in a study by Finn and Lord that occured in response to the ingestion of the human equivalent of 1g/day of sucralse can hardly be considered conclusive evidence in favor of the "sucralose is poison hypothesis (Finn. 2000).
  • The effects Mann et al. describe in a study where 3%-5% of the chow was pure sucralose is devoid of any relevance for our question (Mann. 2000a; Goldsmith. 2000). The same goes for the numerous studies where the lab animals received sucralose in amounts of >500mg/kg body weight (e.g. Finn. 2000; Kille. 2000). For a human being that would be more than 6.5g/day - and that's only if the lab animal was a rodent. For larger animals it would be even more.
    Now, you can always argue that the negative studies just weren't long enough to elicit similar effects at lower dosages or, if you prefer that, work yourself up into a lather about the fact that (conspiracy-)theoretical, all the benficial studies could have been openly funded or secretly supported by people / companies with a vested monetary interest in positive safety data. In fact, the existence of a review of the safety of Splenda the lead author of which works for McNeil Nutritionals, LLC, who market Splenda for Johnson & Johnson (Grotz. 2009), or a "expert panel" review you will read about later in this article actually support that this may be the case, the same can unfortunately be said of almost every food additive - including stevia, by the way.

    Let's get on to potential endocrine effects

    In view of the fact that it is pointless to speculate about the validity of the data from the positive studies in the foregoing list, I want to turn to another, the final and as we are going to see not necessarily more "productive" topic of this third and last installment of my sucralose review trilogy: The endocrine effects.
    Due to sucralose not just vegans (more) may be at risk of low B12
    Sucralose + Vitamin B12: This is not exactly an endocrine effect, but in the end it could become one, when large enough quantities of cobalamine, aka "vitamin B12" react with sucralose in the liver, vitamin B12 deficiency could be a potential side effect. Aside from the in-vitro evidence Motwani et al. present in their 2011 paper in Food and Chemical Toxicology, there is yet no evidence that would suggest that this is actually happening, let alone to an extent that would leave you B12 deficient like a vegan ;-)
    In that, I am using the word "endocrine" in its most general sense, which denotes anything that is produced or directly triggered by an organ and has influence on other organs / tissues or the whole body. The sucralose induced changes in the expression of enzymes from the P450 cytochrome cascade that are responsible for the interconversion / metabolism of all sorts of molecules, including hormones and medications would be one example for such effects.

    To this ends we have to go back to the previously cited study by Abou-Donia et al. (2008), of which I did not tell you in the last installment of this series that it has (obviously) been under heavy attack by toxicology experts who do not necessarily doubt the validity of the study data Abou-Donia et al. present, but claim that their interpretation was irresponsible.
    A brief note on the criticism of the Abou-Donia study: As you'd expect it's no coincidence that  the corresponding paper carries the phrase "expert panel" in it's title. It was after all written and published on request of McNeil Nutritionals, a marketer of retail products that contain the non-nutritive sweetener, sucralose, who paid the "panel of experts" to do a "independent and rigorous review of the 2008 study by Abou-Donia et al." (Brusick. 2009)
    I won't discuss all the objections the "expert panel" proffers. Not because I think that their general objections against hasty conclusions with respect to unwanted negative health effects weren't justified, but rather because I want to get back to Schiffner's & Rother's review, where you'll find the following comment about the CYP-modifiying effects Abou-Donia et al. observed and Brusick et al.'s criticism:
    "The results in Table 1 [identical copy on the right] indicate that the magnitude of elevation for both CYP3A and CYP2D expression increased in a linear, dose-dependent manner as the dosage of sucralose increased from 3.3 to 5.5 to 11 mg/kg/d.

    This finding of significant and parallel increases in expression of two different CYP enzymes does not support the claim made by Brusick et al. (2009) that increases in CYP from sucralose ingestion were only normal biological variations."(Schiffman. 2013)
    In other words: Coincidental increases in CYP activity would not 'coincidentally' be dose-dependent, as well. If we also remind ourselves of the fact that the human equivalent doses of said 3.3, 5.5 and 11mg/kg sucralose would be (only) 43mg, 71mg and 143mg it is self-evident that we cannot simply ignore the acute and persistent increases in intestinal P-gp, CYP3A, and CYP2D (in humans this is CYP2D6; cf. Laurenzana. 1995) in the jejunum and ileum of About-Donia's hairy subjects.

    The obvious question, now, is: Does this even matter?

    I mean, changes in the expression of some cryptic enzymes in the gut - who cares? After taking a look a the list of substrates that are enzymatically processed by CYP3A, alone, even the small 44% increase that occured in response to the rodent equivalent of 43mg appears relevant.

    Figure 1: Important supplement drug interactions | learn more
    On this list are some immunosuppressants, many chemotherapeutics including tamoxifen and anastrazole, which are popular with athletes who use PEDs. There are SSRIs, like citalopram, norfluoxetine, sertraline, other anti-depressants like mirtazapine, or buspirone, the whole list of anti-psychotics, opoids and many analgesics, benzodiazepines, statins like atorvastatin, lovostatin and simvastatin, calcium channel blockers, anti-histamins and even viagra and Co (PDE-5 inhibitors). And even our good old caffeine is on the list of CYP3A4 substrates, on which you'll also find estrogen, testosterone, progesterone, finasteride and torimifene. It's thus not just that your chemotherapy may fail, your depression may return, you may run havoc, hurt all over, increase your cholesterol levels, get high blood pressure, have life-threatening allergic reactions, because your meds are not working properly no (!), even worse caffeine may stop working ;-)

    Unlike the increase in CYP2D6 that simply adds to the sucralose ↔ drug interactions, the corresponding increase in P-gp activity and thus the transport of chemicals from gut cells (enterocytes), back into the intestinal lumen could affect the absorption of an even wider range of both wanted and unwanted chemicals / xenobiotics with a hydrophobic and amphiphilic structure.

    The net result of the increases in CYP and pGP activity is thus a significant decrease in the concentration of a xenobiotic compound on its way from the gastro-intestinal tract to the liver. Whether this amplified "first pass effect" would actually have physiologically relevant consequences in human beings is yet something we cannot tell without somebody paying for the costly research.

    To complicate things, we must not ignore the possibility that "[...t]he rise in CYP expression reported by Abou-Donia et al. (2008) may result from 'autoinduction', by which sucralose enhances it own metabolism." It would thus be a second St. John’s wort, which will also increase its own metabolism by the activation of P-gp and CYP. For Hypericum perforatum extracts, which are often used as mild anti-depressants, we do already know that it affects the metabolism of an endless list of drugs and herbal supplements, and can reduce the levels of 5-alpha reduced androgens like DHT (estrogen and testosterone appear not to be influenced, though; cf. Donovan. 2005).
    So what about toxicity and endocrine disruption? If we discard the potential interference with drugs and consequent "St. John's Wort"-esque side effects, I would say that the dosages that are necessary to actively induce more or less insignificant DNA damage in rodent studies, as well as the absence of any evidence of toxic effects from one of the historical single-dose or short-term sucralose studies in humans (Mezitis. 1996; Baird. 2000) make it appear very improbable that the habitual, but reasonable use of sucralose could have toxic or carcinogenic effects.

    Remember the Science Round-Up from March? The safety of  stevia, is not beyond doubt either | more
    The "benefit of the doubt" is yet no acquittal, it is only my assessment of the reasoning Schiffman & Rother provide in their paper, the relevant parts of which are all based on mere hypothesis, e.g. the "IBD ↔ sucralose"-hypothesis by Qin et al. (2011, 2012), or the "there may arise different more toxic sucralose metabolites in the human vs. rat digestion tract"-hypothesis by Goldsmith (2000) and Mann (2000a) and/or rely on data from the highly disputed Abou-Donia study, the most significant result of which are (imho) still the pronounced changes in the gut microbiome (read more in the last episode of this three part series).

    At the moment, it does yet still look as if you were on the "safer" side if you prefer stevia sweetened products, although I honestly have my doubts that we wouldn't observe similar effects in mice, rats and all sorts lab critters, if 5%+ of their diet was pure stevia. The dosage makes the poison, you better remember that.
    References:
    • Abou-Donia, M. B., El-Masry, E. M., Abdel-Rahman, A. A., McLendon, R. E., & Schiffman, S. S. (2008). Splenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male rats. Journal of Toxicology and Environmental Health, Part A, 71(21), 1415-1429.
    • Brendler-Schwaab, S., Hartmann, A., Pfuhler, S., & Speit, G. (2005). The in vivo comet assay: use and status in genotoxicity testing. Mutagenesis, 20(4), 245-254.
    • Brusick, D., Grotz, V. L., Slesinski, R., Kruger, C. L., & Hayes, A. W. (2010). The absence of genotoxicity of sucralose. Food and Chemical Toxicology, 48(11), 3067-3072. 
    • Brusick, D., Borzelleca, J. F., Gallo, M., Williams, G., Kille, J., Wallace Hayes, A., ... & Burks, W. (2009). Expert panel report on a study of Splenda in male rats. Regulatory Toxicology and Pharmacology, 55(1), 6-12.
    • Biles, R. W., & Piper, C. E. (1983). Mutagenicity of chloropropanol in a genetic screening battery. Fundamental and Applied Toxicology, 3(1), 27-33.
    • Cho, W. S., Han, B. S., Lee, H., Kim, C., Nam, K. T., Park, K., ... & Jang, D. D. (2008). Subchronic toxicity study of 3-monochloropropane-1, 2-diol administered by drinking water to B6C3F1 mice. Food and Chemical Toxicology, 46(5), 1666-1673.
    • Finn, J. P., & Lord, G. H. (2000). Neurotoxicity studies on sucralose and its hydrolysis products with special reference to histopathologic and ultrastructural changes. Food and chemical toxicology, 38, 7-17.
    • Goldsmith, L. A. (2000). Acute and subchronic toxicity of sucralose. Food and chemical toxicology, 38, 53-69.
    • Grotz, V. L., & Munro, I. C. (2009). An overview of the safety of sucralose. Regulatory toxicology and pharmacology, 55(1), 1-5.
    • Motwani, H. V., Qiu, S., Golding, B. T., Kylin, H., & Törnqvist, M. (2011). Cob (I) alamin reacts with sucralose to afford an alkylcobalamin: Relevance to in vivo cobalamin and sucralose interaction. Food and Chemical Toxicology, 49(4), 750-757.
    • Kille, J. W., Tesh, J. M., McAnulty, P. A., Ross, F. W., Willoughby, C. R., Bailey, G. P., ... & Tesh, S. A. (2000). Sucralose: assessment of teratogenic potential in the rat and the rabbit. Food and chemical toxicology, 38, 43-52.
    • Laurenzana, E. M., Sorrels, S. L., & Owens, S. M. (1995). Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6. Drug metabolism and disposition, 23(2), 271-278.
    • Leatherhead Food Research. (2011). The global food additives market, 5th ed., September.
      Leatherhead, Surrey, UK: Leatherhead.
    • Mann, S. W., Yuschak, M. M., Amyes, S. J. G., Aughton, P., & Finn, J. P. (2000a). A combined chronic toxicity/carcinogenicity study of sucralose in Sprague–Dawley rats. Food and chemical toxicology, 38, 71-89.
    • Mann, S. W., Yuschak, M. M., Amyes, S. J. G., Aughton, P., & Finn, J. P. (2000b). A carcinogenicity study of sucralose in the CD-1 mouse. Food and chemical toxicology, 38, 91-97.
    • Rahn, A., & Yaylayan, V. A. (2010). Thermal degradation of sucralose and its potential in generating chloropropanols in the presence of glycerol. Food Chemistry, 118(1), 56-61.
    • Sasaki, Y. F., Kawaguchi, S., Kamaya, A., Ohshita, M., Kabasawa, K., Iwama, K., ... & Tsuda, S. (2002). The comet assay with 8 mouse organs: results with 39 currently used food additives. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 519(1), 103-119. 
    • Scientific Committee on Food. (2001). Opinion of the Scientific Committee on Food
      on 3-monochloro-propane-1,2-diol (3-MCPD). European Commission, Health and
      Consumer Protection Directorate-General. http://ec.europa.eu/food/fs/sc/scf/out91_en.
      pdf (accessed December 14, 2013)
    • Tritscher, A. M. (2004). Human health risk assessment of processing-related compounds in food. Toxicology letters, 149(1), 177-186.
    • World Health Organization. (2002). 3-Chloro-1,2-propanediol. In Safety evaluation of certain food additives and contaminants. WHO Food Additives Series 48. http:// www.inchem.org/documents/jecfa/jecmono/ v48je18.htm (accessed December 14, 2013).

    Better Sip Your Beta Alanine: Decreased Urinary Excretion from Time Released Beta-Alanine Formula.

    Image 1: Tabbing or cabbing, or just washing it down with some water - what is the best way to take your beta alanine?
    If you have been following the supplement scene for quite some time now, you will probably remember headlines such as "Beta Alanine, the next creatine!"... well, the hype which was deliberately fueled by the supp-companies, who realized that the price umbrella on creatine was shriveling, has abated and yet, beta alanine and, of course, creatine are both still there. Compared to the number of studies on creatine monohodrate, which were and still are published on almost a monthly basis, the science on beta alanine and most importantly its mechanism of action is however pretty skinny. I am thus happy to share with you a few interesting findings from two recently published studies - one today, the other tomorrow ;-)

    The more it tingles the less it works... !?

    Despite the fact that I personally like the awkward feeling you get when you take tons of beta alanine, I have always suspected that the "tingling" sensation - whatever its underlying reasons may be - is a very unsatisfactory indicator of whether the supplement "works" or not. After all, there is no physiological reason why the intended recombination of beta alanine + histidine to carnosine and the storage of the latter inside of your muscle tissues would go hand in hand with a "pins and needles" kind of flush. I was thus not surprised to see that Jacques Décombaz and his collegues from the Nestlé Research Center in Lausanne, Switzerland were able to show that ingestion of a "time-released" beta alanine tablet (2x800mg) did not only lead to statistically significant reductions in paraesthesia, but did also reduce the urinary excretion of the carnosine precursor (Décombaz. 2011).
    Figure 1: Beta alanine (BA) serum values in µmol/L in the 6h after ingestion of 1.6 g of BA in solution or as time-released tablet (2x800mg); small graph: area under the curve (data based on Décombaz. 2011)
    As you can see in figure 1, the time-released formulation avoids the rapid increase in beta alanine serum levels (solution: Cmax=248.2µmol/L; tablet: Cmax=81.9) Décombaz et al. observed with a standard solution of 1.6g beta alanine (Carnosyn TM) in aequeous solution.
    Figure 2: Urinary beta alanine excretion (in µmol) in 11 healthy volunteers 0-2h and 2-6h after ingestion of 1.6 g of BA in solution or as time-released tablet (2x800mg); small graph: degree of retention (in % of intake) calculated based on urinary excretion (data based on Décombaz. 2011)
    And although the area under the serum BA curve may be slightly smaller (AUC; figure 1, right), a calculation based on the decreased 6h urinary excretion in the 11 healthy caucasian volunteers (5 women, 6 men) who consumed the time-released preparation (cf. figure 2) reveals that the tissue retention from the tablet formulation was still 2.6% greater. Within the given standard deviations of 0.9% (tablet) and 2.1% (solution), I would yet be very surprised if this would actually make a practical difference as far as the ergogenic effects of beta alanine are concerned.
    Figure 3: Topography of b-alanine-induced sensations. Data shown are the maximal reported values of the body
    surface sensitive score (directly from Décombaz. 2011)
    Of greater practical relevance is thusly the data on the incidence of "side effects" (did I mention that I like the tingling ;-), which - as the cute graphic in figure 3 goes to show - were significantly ameliorated when the subjects ingested their beta alanine in form of the hydroxypropyl methylcellulose, stearic acid, magnesium stearate, and silicon dioxide containing tablet.

    ... and why does it tingle? We still don't know!

    What I personally do yet find more interesting than the reductions in sensory "side effects" are the speculations the scientists make as far as the underlying physiological reasons for the occurrence of the "pins and needles" (this was the prevailing description of the symptoms the study participants used) are concerned:
    There are at least five recognized receptor sites for bA and the mechanism responsible for the sensitization of nociceptive neurons has not been unequivocally clarified [...] candidates include (a) bA-activated strychnine-sensitive glycine receptor sites, in association with glutamate sensitive N-methyl-D-aspartate receptors in the brain and the central nervous system, and (b) the mas-related gene family of G protein-coupled receptors, in dorsal root ganglia neurons ending in the skin, which are triggered by interactions with specific ligands such as bA.
    While option b) sounds relatively harmless, option a) and previous studies reporting profound modulatory effects on brain neurotransmitter levels (esp. serotonin, cf. Murakami. 2010) keep me wondering, if beta alanine does not have more (and potentially harmful) side-effects than the minor paraesthesia.

    So, in essence, we still don't know what it is that causes this feeling some people like, most people ignore and a handful of people hate so much that the time released tablets may in fact provide an adequate (yet obviously more expensive) alternative to powders or caps to max out their carnosine stores while avoiding the inconvenient sensation of "pins and needles" punctuation their flesh.
    Image 2: Time released beta alanine in its natural form
    Dr. Andro's tip for outsmarting the supplement industry: The wise guy (or girl) you are you probably don't really need me to tell you that by just sprinkling your beta alanine over your food or sipping on it in the course of your workout (or your daily routine) you can make your own "time-released beta alanine formula". A formula, of which you could even say that it was "invented by nature itself"... after all, poultry is the richest source of dietary beta alanine, so if you are into the whole ancestral diet concept spicing up your chicken drumsticks with another 1g of bet alanine would be the "paleo way of time-released beta alanine supplementation" *rofl*
    A pros pos maxing out carnosine stores. I suggest you come back tomorrow if you are interested in whether or not doing this is actually worth it. "Unclear", "possibly", "negligible", "likely beneficial", "likely harmful" and the rest of the vocabulary that is used in a recent study from the Department of Exercise and Sport Science at the University of North Carolina to evaluate the effects the scientists observed on acute exercise performance after 28 days of beta alanine supplementation does in any case not sound that enthusiastic.

    Update: Click here for the second part of this beta alanine double-whammy.

    Beyond Vida's Book, Part 2/2: Androgen, Progesterone, Estrogen & Corticosteroid Receptor Activities of ALLmost All Anabolic Steroids - Metabolits, Progestins & More

    Image 1: Tetrahydrogestrinone aka THG,
    aka "The Clear" and the bone of contention
    in the "BALCO Scandal" could probably
    have been identified years before, if the
    WADA detectives already had the new
     mammalian androgen responsive reporter
    gene assays at their disposal.
    As mentioned in part 1 of this post (cf. Beyond Vida's Book, Part 1/2), Houtman and the other scientists from BioDetection Systems B.V. and the Institute of Public Health and the Environment in the Netherlands, did not exactly want to provide juicers with data on which steroids may cause unexpected side-effects, when they conducted their study in 2008. The original idea was to demonstrate that their technology would be able to identify even those androgens, which have hitherto not been classified as illegal substances - so called "designer steroids", which would not turn up in the chemical–analytical approaches combining gas chromatography (GC) or liquid chromatography (LC) separations with mass spectrometry (MS) or tandem mass spectrometry (MS/MS) simply because their molecular structure is hitherto unknown (you cannot find what you ain't looking for ;-).
    This is the second part of a two part series, click here to read more about nandrolone, trenbolone, testosterone and all the androgens on the list of prohibited substances of the World Anti Doping Agency.
    If this method had been available back in the day, when Patrick Arnold developed THG (tetrahydrogestrinone aka "The Clear") for BALCO, the detectives from the World Anti Doping Agency (WADA) would probably have been able to identify Marion Jones and other athletes who used this highly performance-enhancing drug, even before baseball star Berry Bonds blew the whistle in 2001.
    Figure 1: Relative potency at the androgen (compared to testosterone), progesterone (compared to progesterone) and estrogen alpha and beta receptors (compared to estrogen) of "The Clear" (THG), trenbolone and nandrolone
    (calculated based on data from Houtman. 2008)
    Now, more than 10 years later, THG is on the list of WADA prohibited compounds and we know that "The Clear" is 0.25x as androgenic as dihydrotestosterone and 1.15x more androgenic than testosterone. We also know that THG is a powerful progestin, with 91% of the receptor activity of "real" progesterone (trenbolone has 35%), but hardly any translational activity at the level of the estrogen (0.0017% for estrogen-beta) and corticosteroid receptor.
    Figure 2: Relative potency (new reference:
    progesterone!) of steroids not on the
    WADA list at the progesterone receptor
    (data calculated base on Houtman. 2008)
    A few notes on the graphs: Houtman et al. did not measure the relative potency at the progesterone receptor for all of the "other exogenous androgens". Instead of meshing androgen and progesterone activity into a single graph, I thus decided to seperate the two, because otherwise it would have been difficult to identify which of the steroids actually have "zero" transcriptional activity at the progesterone receptor and which just have not been analyzed by the scientists. Additionally I recalculated the references using testosterone and progesterone instead of DHT and the over-potent progestin ORG2085.

    Among the better known other (I am sticking to Houtman et al.'s nomenclature, here) exegenous androgens, the Dutch scientists analyzed, trestolone, or 7a-methyl-19-nor-T (MENT), is certainly the "meanest bitch". It's androgenic activity is almost 10x higher than that testosterone (and thus 3x more potant than nandrolone!) and its potency as a transcriptional activator at the level of the progesterone receptor is still 29% of that of progesterone and thus more than 9x higher than that of nandrolone aka "Deca".

    Figure 2: Relative potency at of steroids
    not on the WADA list at the androgen
    receptor; note that I re-calculated the
    values relative to testosterone as a new
    reference
    , this means that you have to
    divide the values by 4.68 to get DHT as
    a reference, as in Part 1, fig. 2 (data
    calculated base on Houtman. 2008)
    The major offenders, as far as chances of immediate (cf. red box in part 1 of this article) progesterone-related side effects are concerned, are yet the norethisterone derivatives (relative potencies compared to progesteron)
    1. 11b-ethynyl-NET - 880%
    2. delta-15-NET - 290%
    3. 11b-ethenyl-NET - 262%
    4. 6a-methyl-NET - 253%
    5. 11b-I37ethyl-NET - 139%
    I guess, you probably already suspect that these are agents in progesterone-only or combined contraceptive pills. So, in essence nothing athletes will be using.

    The 7-alpha-methylated derivate of the progestin nethisterone, 7a-methyl-NET, however, has an androgen/progesterone activity ratio of 427/8. Now, although the respective values for trenbolone and nandrolone are only 442/35 and 327/7 this does not necessarily go to tell you that it would make a powerful mass builder, especially in view of the results of previous studies using CHO-AR reporter gene assays, according to which nandrolone (I do not have data on trenbolone, here) has a 1.6x higher androgen receptor binding affinity than the aforementioned nethisterone derivate.
    Image 2: The dissection of the
    prostate (image by Gray. 2005) is
    an unsavory, yet obligatory part
    of the Hershberger assay, an in-
    vivo method to evaluate the
    androgenic activity of steroids
    that was developed by
    T.V. Hershberger in the 1960s.
    Different tests, different results: Most of the data you will currently find on message-boards and certain webpages is based on the "old" CHO-AR reporter gene assays, the results of which often contradict relative activity levels measured by AR CALUX. According to the CHO-AR gene assay, for example the nandrolone would be the more potent androgen receptor agonist (2.65x more potent, Sonneveld. 2005). According to the Chemical Activated Luciferase gene eXpression test, on the other hand, its almost the other way around. Lastly, according to the good old Hershberger-test, which was developed in the 1960 and '70s as an in-vivo procedure to evaluate the androgenic activity of steroids in rats, 7a-methyl-NET has 6.25x the androgenic activity of nandrolone. While it is likely that the CALUX assay is the most reliable method, when it comes to the exact cellular mechanisms, the good old Hershberger-tests, Julius Vida (the "Vida" from "Vida's Book") used, as well, still have their merit, as they provide some insight into what may happen when the compound is administered to an actual living organism.
    Similar to the WADA-prohibited compounds, where with the exception of 4-chloro-19-nor-T, 19-norclostebol (4%) and 19-nor-androstenediol (1%) most of the compounds that have been tested exhibited <1% of the receptor activity of estradiol at both the estrogen beta and alpha receptors, compared to estradiol none of the tested (estrogen receptor transcriptional activity was measured for only 10 out of 36 androgens) compounds had significant estrogenic activity. 7a-methyl-NET, the progestin discussed in the previous paragraph, for example has a relative potency of 0.038%, which is more than 4x higher than the 0.009% potency of nandrolone, yet still less than half of the activity of DHEA (0.081%).
    Figure 3: Relative potency of steroid metabolits at the androgen receptor, note that I re-calculated the values relative to testosterone as a new reference, this means that you have to divide the values by 4.68 to get DHT as a reference, as in Part 1, fig. 2 (data calculated base on Houtman. 2008)
    Similarly, out of the less-androgenic (cf. figure 3) metabolites and isomers Houtman et al. actually tested, only 5a-androstane-3b,17b-diol (0.543%) and 4-androstenediol (4-AD) (0.125%) presented significant interactions with the estrogen beta receptor (0.039% and 0.012% at the alpha receptor).

    If I may remind you of the the high transcriptional activity of nandrolone and trenbolone, I've discussed in the first part of this article, which corresponds well with the progesterone related side-effects many athletes complain about, the relatively high activity of 4-AD at the estrogen receptor (25x higher than testosterone) in the CALUX assay is yet another sign for the real-world relevance of the luciferase assay data (cf. red box "Different tests, different results"). After all, androst-4-ene-3b,17b-diol, which happens to be one of the pro-hormones that has lately re-appeared on the "supplement" market, is well-known to be one of the "wetter" compounds.
    Figure 4: Relative potency of several natural and synthetic steroids at the corticosteroid receptor with cortisol as a reference (data calculated based on Houtman. 2008)

    Finally, we will have a brief look at those steroids which mess with the glucocorticoid receptor. Other than the usual suspects in figure 4, only fluoxymesterone (0.27%), 5a-hydrogen-11b-methyl-NET (0.52%), 11b-methyl-19-nor-T (1.97%), 7a-methyl-19-nor-T aka "Trestolone" or "MENT" (1.56%) and progesterone (0.65%) exhibit any notable corticosteroid activity (expressed relative to the potency of cortisol). However, nandrolone, trenbolone and other anabolics with progestational activity appear to exert indirect effects on the mammalian corticosteroid metabolism (Moor. 1971) and may thus induce downstream effects the CALUX assay obviously cannot detect (suggested read: red box on DHEA and aromatization in part 1 of this article).

    With the issue of literal "side-effects", i.e. effects not related to direct transcriptional activity at the receptor sites, I want to conclude this two part series on the immediate effects of a broad range of androgens on androgen, progesterone, estrogen and corticosteroid receptors by reminding you of the fact that despite an ever-increasing accuracy and the constant development of even more sophisticated analytical methods, there still is (and probably never will be) a machine, where you insert a certain molecule, press a few buttons and get a print out that says: "Person A; age: 25, sex: male; training: 5x a week; nutrition: [...] will gain Xlbs of lean mass and shed Ylbs of fat on a Z-week cycle of XYZmg of compound ALPHA".

    Beyond Vida's Book, Part 1/2: Androgen, Progesterone, Estrogen & Corticosteroid Receptor Activities of ALLmost All Anabolic Steroids - WADA Prohibited Compounds.

    Image 1: Data on the interaction of androgens
    with the progesterone receptor is scarce,
    this study has it!
    This is only blogpost #499, yet at the same time, its a premiere! It's the first time that I am aware of that something you read at the SuppVersity has been covered by the "competition" before. Kudos to my dutch friends from ergogenics.org, who dug up a 2008 paper by Corine J. Houtman et al. (Houtman. 2008) with extensive CALUX(R) bioassay data on the androgen, progesterone, estrogen and corticosteroid receptor response to allmost all popular steroids - it would probable be the "A", as in 4-androstenediol (the "good old 4-AD"), to "Z", if there actually was a common androgen with a "z" as its first character.
    Note! Due to the fact that the sheer amount of data from this study exceeds the time I can spend on analyzing and compiling it for you, today, this is going to be a two part series, with the second part on what the authors describe as "potential" AAS (among these are such illustrious names as 7a-methyl-19-nor-T aka Trestolone or MENT) will follow tomorrow. And don't get mad at me for that, at least it does have the advantage that you can comment / pose questions today and have them answered in detail, by tomorrow ;-)
    The original intention of the study obviously was to demonstrate that by the means of the mammalian androgen receptor responsive reporter gene assay (AR CALUX® bioassay), the anti-doping agency would be able to identify hitherto unknown "designer steroids", which would not show up in the usual tests, where the chemical structure of the substance you are looking for must be known beforehand. The CALUX bioassay, on the other hand, directly measures the transcriptional activity of a specific steroid receptor when it is exposed to a given substance and is thus a very reliable measure of the biological effect a certain anabolic will have on the cellular level.
    Figure 1: Enzymes, their cellular location,
    substrates and products in human
    steroidogenesis
    ; DHEA is the first
    compound in the left androgen column
    (figure by Slashme and Mikael Häggström)
    While it is of course grandiose to be able to measure receptor activity directly, a non-negligible weakness of these bioassays is that they do not provide any insight into the effects of downstream-metabolits of the tested androgen. Let's take dehydroepiteandrosterone (DHEA) as an example. It is well known that after several enzymatic reactions DHEA can eventually be converted to estrogen (cf. figure 1), if however you measure the transcriptional activity of DHEA at the estrogen receptor it turns out to be 0.0813% of 17β-Estradiol (E2). This example clearly shows that, at least in the case of aromatizeable steroids such as DHEA, CALUX provides only part of the overall picture. Keep that in mind, when you are trying to interpret the data!
    Other than "Vida" in his famous rat studies, these assays obviously do not provide any information about the "anabolic" value of the respective compounds. Oxandrolone, for example, is known as a highly anabolic steroid, which has about 6x the anabolic activity of testosterone. Nevertheless, its activity at the androgen receptor is only 1% of that of dihydro-testosterone (DHT) and thus no more than 1/20 of the androgen receptor activity of testosterone (cf. figure 2). Accordingly, the following data will not really tell you how much muscle an athlete will be able to accrue whilst taking a certain steroid, but rather which androgen, progesterone, and estrogen related side-effects he or she may experience in the course of that cycle.

    Figure 2: Relative potency at the
    androgen (reference: DHT) and
    progesterone (reference: ORG2085)
    receptor of androgens that are
    officially prohibited by WADA
    (based on Houtman. 2008)
    If you have a look at the androgens from the WADA's list of prohibited compounds in figure 2, you will notice that compared to the synthetic progestin 16a-ethyl-21-hydroxy-19nor-4-pregnene-3,20-dione (ORG2085) only a handful of compounds exhibits a significant transcriptional activity at the progesterone receptor:
    • 17a-ethyl-19-nor-T (norethandrolone) - 24%
    • norbolethone - 21%
    • tetrahydrogestrinone (THG) - 7%
    • gestrinone - 5%
    • 17b-trenbolone - 3%
    If the occurrence of trenbolone as the last item on the list of androgens with a high activity at the level of the progesterone receptor puzzled you, you obviously have not heard of the dreaded "progestin-gyno" this powerful steroid is supposed to induce!? While 3% of the activity of a synthetic progestin does not sound much, trenbolone is a 6423x more potent activator of the progesterone receptor than testosterone and it is still 525x more active than nandrolone aka "deca", another of the commonly used mass and strength agents the use of which is rumored to have induced gynecomastia in a non-negligible number of drug using athletes.

    Only 4-chloro-19-nor-T, 19-norclostebol (4%), 19-nor-androstenediol and methyl-androstenediol (0.1%) exhibit transcriptional activity >0.1% of that elicited by estradiol at the estrogen alpha and beta receptors and none of the tested androgens from the WADA list has an activity >0.002% (this is fluoxymesterone) of that of dexamethasone at the corticosteroid receptor. In order not to overcomplicate things, I have decided to exclude this additional data from figure 2.
    This is only part 1! Don't forget to check back tomorrow for more information on metabolites and isomers, such as 4AD & Co., other exogenous androgens that are not yet on the WADA anti-doping list, such as 7a-methyl-19-nor-T (Trestolone,  MENT) and other steroids!

    Androstenedione, Grand Daddy of All Prohormones: Carcinogenic Poison or Non-Toxic Muscle Builder?

    I suspect you have already read statements like "prohormones will kill your liver", "prohormones will give you gyno" and/or "prohormones will induce prostate cancer", haven't you? Well, Androstenedione is not methylated, so bro-science would tell you that your liver won't take a beating. Yet, all gynecomastia issues aside, what if its not the methyl-group but the prohormone itself that is liver toxic or carcinogenic? A recent study published in the journal of Food and Chemical Toxicology on May 30 2011 (Blystone. 2011) sheds some light onto potential side effects of the "grand daddy of all prohormones".

    Chard R. Blystone and his colleagues administered  "subchronic" doses of androstenedione @ 10, 20, or 50 mg/kg body weight to male and @ 2, 10, or 50 female mice. And they did that for two years.
    Figure 1: Cancer risk of male F344/N rats after 2 years of chronic exposure to androstenedione at 10, 20, or 50mg/kg body weight relative to 0mg control (data adapted from Blystone. 2011)

    To put that into perspective, an average androstenedione cycle lasts anywhere from 4-8 weeks and dosages range from 100-600mg/day, considering the fact that the average laboratory rat weighs about 300g and the human equivalent dose of the highest, 50mg/kg dose, is 8.1mg/kg (this would equal a 650mg daily dose for a 80kg human being), the rats receiving 50mg/kg androstenedione per day for two years were exposed to the equivalent of 473513.51mg or roughly 440g of androstenedione. In their abstract the scientists summarize their observations as follows:
    Increased incidences of lung alveolar/bronchiolar adenoma and carcinoma occurred in the 20 mg/kg male rats and increases in mononuclear cell leukemia occurred in the 20 and 50 mg/kg female rats, [...]. In male and female mice, androstenedione was carcinogenic based upon a significant increase in hepatocellular tumors [cancerous growth in the liver]. A marginal increase in pancreatic islet cell adenomas in male (50 mg/kg) and female (2, 10, 50 mg/kg) mice was considered to be related to androstenedione administration.
    While this does sound pretty dangerous looking beyond the abstract and at the actual data, part of which I plotted for you in figure 1, does yet speak a very different language. Although the scientists also mention that to their own surprise androstenedione decreased "incidences of male rat Leydig cell adenomas and female rat mammary gland fibroadenomas", they did not mention that it did so (if not always in a statistically significant manner) in mononuclear cell leukemia and interstitial cell adenoma, as well (cf. figure 1). While the situation is somewhat different in female rats (who would have suspected that supra-physiological doses of testosterone //this is what andro will initially convert to// would be bad for female mice ;-), this is another incidence, where someone who relied solely on the abstract, would be fooled into overestimating the negative and to underestimate unexpected positive effects of a drug that has been vilified like very few compounds before it.

    In view of these results, some bros may now argue that taking androstenedione could actually be beneficial for your health, "protecting" you from several types of cancer! Well, before you jump on that bandwagon, remember that these are probably the same bros of whom you will read on various boards, that they use androstenedione or similar "mild" prohormones to fill the gaps between cycles of much harder steroids... As a reader of the SuppVersity, you get the facts, the interpretations and, even more importantly, the real world choices you make are up to you.

    Caffeine - 3mg, 6mg or 9mg/kg? What's the Optimal Dosage for Lifting & HIT Cycling and What About the Side Effects?

    Wouldn't a single 200mg caffeine be enough to elicit the desired ergogenic effects without side effect like increased urination, headaches and muscle aches on the day after?
    Caffeine is not only the world's #1 it is probably also the most (ab-)used ergogenic on the planet and whatever you may think about the longterm consequences of its use, there is not debating that it is part of those few "supplements" that actually work "no hype, no *bs*" ;-)

    That being said, you may have noticed with yourself that its effect are dose dependent, but not linearly and that some things, such as an increase in mental focus at work require much lower doses of C8H10N4O2 aka 1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione or 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione than the elucidation of a major buzz before an intense strength workout.

    So what's the perfect dose, then?

    Without wanting to hurt your feelings, you may imagine that you are not the only one who has come to this realization. In fact, the very same thought must have occurred to Jesús G. Pallarés and his colleagues from the University of Castilla-La Mancha and the Spanish Antidoping Agency, as well. With a whole host of technological equipment and the money to conduct a study with thirteen highly resistance train men (age 21.9 ± 2.9; 76.5 ± 8.5 kg, height 172.7 ± 5.4 cm, body fat 12.4 ± 2.7), the Spanish scientists are yet in a much better position to elucidate where exactly these sweet spots would be.
    Figure 1: Illustration of the procedure on the testing days (Pallarés. 2013)
    To this ends, Pallarés et al. had their volunteers undergo a battery of muscle strength and power tests, namely a  free-weight fullsquat (SQ) and bench press (BP) exercises against  4 incremental loads (25%, 50%, 75% and 90% 1RM), as well as a test in which their cycling peak power output (PPO) was measured using a 4s inertial load test in a randomized in a double-blind, cross over design.

    On the four separate testing days, the subjects ingested either a placebo supplement (PLAC) or, caffeine at dosages of ...
    • 3mg/kg body weight (CAFF3mg), 
    • 6mg/kg body weight (CAFF6mg) and
    • 9mg/kg body weight (CAFF9mg)
    The day before and during the seven days that the experiment lasted, the subjects lived at the sports performance center where they slept and ate all meals. They all consumed a diet of 2800-3000 kcal·day/day that had a macronutrient make-up where 55% energy intake came from carbohydrates, 25% from fat and 20% from protein. The energy intake was evenly distributed across three meals each day (breakfast at 7:00 a.m., lunch at 13:30 p.m. and dinner at 20:00 p.m.). Subjects refrained from physical activity other than that required by the experimental trials, and withdrew from alcohol, tobacco and any kind of caffeine intake 10 days before testing and while the experiment lasted.

    On the actual testing day some baseline measurements, such as height, body fat %, as well as blood and urine samples were taken (PRE). Afterwards the subjects consumed a standardized "breakfast" consisting of a 330 mL of fruit milkshake (168 kcal) and a pastry (456 kcal; total energy for both 624 kcal; 68 g of carbohydrates) along with the their individualized randomized caffeine dose (3, 6 or 9 mg/kg) or placebo in capsule form. After this "delicious" *lol* breakfast, the participants performed
    "[...] a standardized warm-up that consisted of 10 min of jogging at 10 km/h and 10 min of static stretches and joint mobilization exercises, the subjects entered the laboratory to start the neuromuscular test battery assessments under a paced schedule (see figure 1).  These tests consisted of the measurement of bar displacement velocity and muscle power output against 4 incremental loads (25%, 50%, 75% and 90% of 1RM) for upper and lower body musculature (BP and SQ).  Those step measures allowed a continuous representation of the load-velocity and load-power curves to study the interaction between load and caffeine dose on neuromuscular performance.  Cycling peak power output (PPO) was assessed next using a nonfatiguing inertial load test of 4 s duration.  Subjects remained blinded to the results during the whole experiment. Instructions prior to lifting were standardized and always delivered by the same experimenter.
    The whole procedure took about 60min and upon completion of the test battery a second  urine  and  blood  sample  was  collected  (POST). Moreover, all participants were required to fill out an obligatory questionnaire (QUEST+0h) that was aimed to address whether side-effects of caffeine were present during the trial.

    Caffeine a side effect free ergogenic? Not exactly, no...

    As some of you may know from their own lingering experience things that work, usually don't do that without side effects and the study at hand confirmed that this is no different for caffeine. Somewhat surprisingly, though the side effects the subjects who had refrained from caffeine intake for at least 10 days before the the first test, reported "very similar side effects" for the medium and high dose caffeine trials:
    • a limited increase in the sensations of tachycardia and heart palpitations,
    • self-reported urine output and gastrointestinal problems (8% of the subjects)
    At the same time, the subject’s perception of performance and vigor increased 5 to 7 times above PLAC during the CAFF 3mg and CAFF6mg trials (38% and 54% of the subjects, respectively), which would appear to be well worth the minor problems.

    Figure 2: Overview over the number of participants reporting side effects / perceived ergogenic effects (Pallarés. 2013)
    In the course of the 9mg trial (remember: this was a bolus of 693mg caffeine for the average study participant) the men did yet report a "drastic increase" of side-effects (Table 1), of which the researchers consider the reported increase in the estimates of urine output and gastrointestinal problems (62% and 31%, respectively) to be most important. So important, in fact that it is questionable whether that was worth the increased perception of performance and vigor or activeness of 62% and 54%.

    On the subsequent day, participants in the CAFF6mg trials were complaining of increased muscle soreness, headaches and an increase in the estimates of urine output in comparison to the PLAC and CAFF3mgtreatments. Sleep problems and persistently increased vigor occurred only in the  CAFF6mg an CAFF9mg trials with a much higher incidence (23-54% vs. 8% in the high vs. medium dose trial).

    What Pallarés et al. find particularly noteworthy is that "23% of participants reported tachycardia and anxiety or nervousness, 38% with gastrointestinal problems and 54% with insomnia or sleep disturbances" (Pallarés. 2013). This is also the main reason that the researchers recommend "administering the minimal ergogenic dose". But what exactly is this dosage?

    What delivers the most bang with the least side effects?

    In order to answer this question we will have to take a closer look at the performance measures and compare the increases in mean propulsive velocity and muscle power, as well as the cycling PPO and the likelihood and severity of side effects for all four dosing regimen (see figure 3)
    Figure 3: Propulsive velocity during bench presses (left) and propulsive power during bench presses and squats (right) in the placebo, 3mg, 6mg and 9mg trials (Pallarés. 2013)
    As the data in figure 3 goes to show you, caffeine produced ergogenic effects at all dosages. With the heaviest weights, however, the propulsive velocity during bench presses and the squat power required the side-effect laden 9mg dose of caffeine to reach statistical significance. The same goes for the cycling peak power output (not shown).

    Suggested read: "Coffee - The Good, The Bad & The Interesting: 2-4 Cups of Coffee for Adiponectin. Roasted Filtered Coffee & High LDL!? The Optimal Caffeine / Taurine Ratios & the Buzz ". Could taking taurine ameliorate w/out compromising the benefits of caffeine (read more)?
    Bottom line: The study at hand is actually a good example of the myriad of cases, where statistical significance and the real world collide. Let's take another look at the results in figure 3 and the side effects in figure 2. Assuming that you have not whacked your adrenal gland to an extend that you don't respond to caffeine any longer (in that case you better stop taking it all along, anyway), there clearly is no reason to even remotely consider taking caffeine in dosages of more than 6mg/kg body weight before a workout (personally I have found that anything beyond 200-300mg will - in the long run do more harm than good for me, but I guess this really depends on the individual).

    Aside from the subjective side-effects the latter has also been shown to have profoundly detrimental effects on the cortisol to testosterone ratio after a workout (cf. "Revisited: Caffeine's Dose-Dependent Effects on the Testosterone to Cortisol Response to Exercise"; read more)...

    ... and yes, I know that the relevance of this ratio in terms of the "productivity" of your workouts is highly questionable, the latter has been proven for a normal, non-stimulant based increase in cortisol / testosterone, not for the exorbitant increase in cortisol Beavan et al. observed in their 2008 study. If you add the detrimental down-stream effects of messed up sleep, and the obvious dehydration that follows the increased urination observed in the study at hand - overdosing may thus well turn the "proven ergogenic" caffeine into a highly ergolytic agent.

    References:
    • Beaven CM, Hopkins WG, Hansen KT, Wood MR, Cronin JB, Lowe TE. Dose effect of caffeine on testosterone and cortisol responses to resistance exercise. Int J Sport Nutr Exerc Metab. 2008 Apr;18(2):131-41. 
    •  Pallarés JG, Fernández-Elías VE, Ortega JF, Muñoz G, Muñoz-Guerra J, Mora-Rodríguez R. Neuromuscular Responses to Incremental Caffeine Doses: Performance and Side Effects. Med Sci Sports Exerc. 2013 May 10.

    CLA For Weight Loss: Safe, but Ineffective. Conjugated Linolic Acid Fails to Improve Body Composition or Lipid Profile in 8-Week Human Study

    The early 2000s were the fat years: "Want to lose fat? Eat fat!" became the credo of more and more nutritional gurus, who put their faithful clients "on" EFAs, PUFAs and a certain fatty acid (FA) that, despite, or rather due to its presence in our food chain, had hitherto received little attention by the medical orthodoxy: conjugated linoleic acid (CLA). All of a sudden, this "unhealthy" trans-fatty acid that can be found in relatively large amounts in high fat milk products, was supposed to become the magic bullet in every dieter's fight against unhealthy or unaesthetic body fat.
    So, is the majority of the Americans in the 21st century going to be obese, simply because they are not consuming enough CLA? A recent study from Canadian scientists (Jones. 2011) suggests otherwise.

    In a 3-phase crossover trial, Jones et al. recruited 27 overweight (BMI ≥ 25 kg/m2), borderline hypercholesterolemic [LDL-cholesterol (C) ≥ 2.5 mmol/L] men aged 18–60 y, who consumed during three consecutive 8-wk phases (with a 4-wk washout period between each trial) either 3.5 g/d of safflower oil (control) or a 50:50 mixture of trans 10, cis 12 and cis 9, trans 11 (c9, t11) CLA:Clarinol G-80, and c9, t11 isomer:c9, t11 CLA.

    Figure 1: Chemical structure of the 2 isomers of conjugated linoleic acid (CLA)
    and the unconjugated form linoleic acid (LA)
    (image from Kent. 2007)

    Body weight, body fat, and lean body mass (all reliably measured by DXA), CLA's effects on fatty acid oxidation, as well as blood lipid profiles and safety biomarkers, including insulin sensitivity, blood concentrations of adiponectin, and inflammatory markers (high sensitive-C-reactive protein, TNFα, and IL-6) and oxidized-LDL were assessed at the beginning and end of each trial. The results were unimpressive:
    Compared with the control treatment, the CLA treatments did not affect changes in body weight, body composition, or blood lipids. In addition, CLA did not affect the β-oxidation rate of fatty acids or induce significant alterations in the safety markers tested.

    Or, in other words, CLA supplementation @ 3.5g/day did not produce any of the favorable effects potential customers are promised by the advertisements of an industry that thrives on the hopes of overweight of millions of obese individuals world-wide.

    A conclusive evaluation of both the effectiveness, as well as the safety of CLA would require further studies using and comparing the effects of different  mixtures of the different CLA isomers that  have been found to exert very different metabolic effects - with the trans-10, cis-12 isomer having a more pronounced effect on PPAR-gamma induced metabolic changes (Hermann. 2009) and more compelling evidence of possible negative side effects, such as increased oxidative stress (Risérus. 2007).

    So, after all. The verdict on CLA is still out there! And you know: The SuppVersity is the place, where you will hear about future research first.